Percentage of late-stage R&D
projects with access plans
80
79
GSK
Johnson & Johnson
69
63
Pfizer
Takeda
57
Novartis
Percentage of late-stage R&D projects with access plans
80
79
69
GSK
Johnson & Johnson
Pfizer
63
57
Takeda
Novartis
GSK leads the top five companies with access planning to provide
medicines to low- and middle-income countries
Percentage of late-stage R&D projects with access plans
80
79
69
63
57
GSK
Johnson & Johnson
Pfizer
Takeda
Novartis